HOME ACCESS' OTC HIV TESTING SERVICE SALES IN NEW YORK, CALIFORNIA MAY BE DELAYED BY STATE LAWS; FIRM SEEKS FEDERAL PREEMPTION RULING FROM FDA
This article was originally published in The Gray Sheet
Executive Summary
Home Access Health's over-the-counter sales of its home HIV-1 testing service could be delayed in New York and California, two of the largest markets for the products, due to clinical testing requirements in the two states. The company submitted a request for an "expedited advisory opinion" to FDA on Aug. 16 seeking a determination that the agency's premarket approval of the tests preempts the state requirements.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab With 15 New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.